15 september 2021: Zie ook dit artikel: https://kanker-actueel.nl/tcm-traditionele-chinese-kruiden-zouden-kunnen-helpen-tegen-de-gevolgen-van-het-corona-virus-zeggen-chinese-onderzoekers.html

Betrouwbare adressen van TCM artsen en acupuncturisten staan hier: 


Zie ook TCM studies specifiek bij longkanker.

15 september 2021: Bron: PLOS one Published: August 20, 2021

Veel onderzoeken hebben aangetoond dat TCM - Traditionele Chinese Medicijnen (kruiden) in combinatie met een westerse aanpak  bij de behandeling van milde tot matige COVID-19 - coronavirus superieur was aan westerse aanpak alleen. Dit blijkt uit een meta-analyse van 12 gerandomiseerde studies bij totaal 1393 patiënten die besmet waren met het coronavirus - Covid-19.

De kenmerken van de opgenomen RCT's staan vermeld in  (Table 1). In alle opgenomen studies kregen de patiënten in de controlegroep een conventionele westerse behandeling, terwijl patiënten in de behandelingsgroep een combinatiebehandeling van TCM - Traditionele Chinese Medicijnen en conventionele westerse behandeling kregen. De duur van de behandeling varieerde van 5 tot 15 dagen. Van de twaalf RCT's [1526] waren er studies verdeeld over meerdere ziekenhuizen [181922]  en de overige negen waren uitgevoerd in 1 ziekenhuis. 

In deze review werden negen oraal in te nemen TCM kruiden gebruikt: Jinhua Qinggan granule [15], Toujie Quwen granule [1617], Jinyinhua oral liquid [1825], Lianhua Qingwen capsule (granule) [1923], Maxing Xuanfei Jiedu Decoction [20], Lianhua Qingke granule [21], Reyanning mixture [22], Jiawei Dayuan Decoction [24], diammonium glycyrrhizinate [26].

Zie Table 2. https://doi.org/10.1371/journal.pone.0256429.t002

De top 3 gerangschikte Chinese kruiden die het meest waren gebruikt waren kamperfoelie (58,33%) [15192325 forsythia (50,00%) [1517192123]en ephedra (50,00%) [1519212324].

Vier doseringsformuleringen van orale TCM werden opgenomen, waaronder granulaat [1517212324], orale vloeistof [182225], capsule [1926] en afkooksel  [20]. De meest gebruikte doseringsformulering was granule (50,00%) [1517212324]

Een van de belangrijkste verschillen werd gevonden bij het maken van een long CT. Dit is de originele tekst uit het studierapport:

Clinical efficacy.

Lung CT. The evaluation criteria for a lung CT refer to the COVID-19 Guidelines for Imaging Assisted Diagnosis [27]. Lung CT can evaluate the curative effect through the parameters basic absorption, improvement, no change, and aggravation. If the lesion range disappears ≥70%, it indicates basic absorption. If the lesion range disappeared ≥30%, it indicates improvement. If there was no change in the lesion range, it indicates no change. If the extent of the lesion increased by ≥30%, it indicates aggravation. The effectiveness of therapy based on lung CT = (basic absorption cases + improvement cases)/total cases × 100%. Seven trials enrolling 845 patients mentioned lung CT [161924]. A fixed-effects model was used due to no significant heterogeneity (I2 = 8%, P = 0.37). Meta-analysis revealed that combination therapy could significantly improve lung CT [RR = 1.26, 95%CI (1.15, 1.38), P<0.00001] (Fig 3a). Subgroup analysis showed that there was a significant difference between subgroups with 7 days of treatment duration (P = 0.03) and 10 to 14 days of treatment duration (P<0.00001) (Fig 3a).


Fig 3.

Forest plot of the effects of combination therapy for outcomes of (a) lung CT, (b) clinical cure rate, (c) rate of conversion to severe cases, (d) viral nucleic acid testing.


In het orginele studierapport, gepublicerd in PLOS one en peer reviewed, staan veel meer details en grafieken. Klik op de titel van het abstract voor het volledige studierapport:

Published: August 20, 2021



Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic since its outbreak in Wuhan, China. It is an urgent task to prevent and treat COVID-19 effectively early. In China’s experience combating the COVID-19 pandemic, Chinese herbal medicine (CHM) has played an indispensable role. A large number of epidemiological investigations have shown that mild to moderate COVID-19 accounts for the largest proportion of cases. It is of great importance to treat such COVID-19 cases, which can help control epidemic progression. Many trials have shown that CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 was superior to conventional therapy alone. This review was designed to evaluate the add-on effect of CHM in the treatment of mild to moderate COVID-19.


Eight electronic databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the Clinical Trials.gov website, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Database and China Biology Medicine (CBM) were searched from December 2019 to March 2021 without language restrictions. Two reviewers searched and selected studies, and extracted data according to inclusion and exclusion criteria independently. Cochrane Risk of Bias (ROB) tool was used to assess the methodological quality of the included RCTs. Review Manager 5.3.0 software was used for statistical analysis.


Twelve eligible RCTs including 1393 participants were included in this meta-analysis. Our meta-analyses found that lung CT parameters [RR = 1.26, 95% CI (1.15, 1.38), P<0.00001] and the clinical cure rate [RR = 1.26, 95%CI (1.16, 1.38), P<0.00001] of CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 were better than those of conventional therapy. The rate of conversion to severe cases [RR = 0.48, 95%CI (0.32, 0.73), P = 0.0005], TCM symptom score of fever [MD = -0.62, 95%CI (-0.79, -0.45), P<0.00001], cough cases [RR = 1.43, 95%CI (1.16, 1.75), P = 0.0006], TCM symptom score of cough[MD = -1.07, 95%CI (-1.29, -0.85), P<0.00001], TCM symptom score of fatigue[MD = -0.66, 95%CI (-1.05, -0.28), P = 0.0007], and CRP[MD = -5.46, 95%CI (-8.19, -2.72), P<0.0001] of combination therapy was significantly lower than that of conventional therapy. The WBC count was significantly higher than that of conventional therapy[MD = 0.38, 95%CI (0.31, 0.44), P<0.00001]. Our meta-analysis results were robust through sensitivity analysis.


Chinese herbal medicine combined with conventional therapy may be effective and safe in the treatment of mild to moderate COVID-19. More high-quality RCTs are needed in the future.


  1. 1.Sattler A, Angermair S, Stockmann H, et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition [J]. J Clin Invest, 2020,130(12):6477–6489. pmid:32833687
  2. 2.World Health Organization. WHO Coronavirus (COVID-19) Dashboard.2021 [EB/OL]. https://covid19.who.int/ (accessed Mar 26, 2021).
  3. 3.You C, Deng Y, Hu W, et al. Estimation of the time-varying reproduction number of COVID-19 outbreak in China [J]. Int J Hyg Environ Health, 2020,228:113555. pmid:32460229
  4. 4.Ni L, Chen L, Huang X, et al. Combating COVID-19 with integrated traditional Chinese and Western medicine in China [J]. Acta Pharm Sin B, 2020,10(7):1149–1162. pmid:32834946
  5. 5.Gao XM. Traditional Chinese Pharmacy (advanced series of traditional Chinese medicine) [M]. Beijing: People’s Health Publishing House, 2000.
  6. 6.Diagnosis and Treatment Guideline for COVID-19 (Trial 8th Edition) [J]. Chin J Viral Dis, 2020,10(05):321–328.
  7. 7.Wu ZY, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China [J]. J Am Med Assoc, 2020, 323(13): 1239–1242.
  8. 8.Tian J, Yan S, Wang H, et al. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study [J]. Pharmacol Res, 2020,161:105127. pmid:32791263
  9. 9.Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial [J/OL]. Phytother Res: 7141[2021-05-12]. https://pubmed.ncbi.nlm.nih.gov/33979464/
  10. 10.Xin S, Cheng X, Zhu B, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment [J]. Biomed Pharmacother, 2020,129:110500. pmid:32768975
  11. 11.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [J]. Ann Intern Med, 2009,151(4):264–W64.
  12. 12.Higgins JPT, Green S. Cochrane Reviewers’ Handbook 5.3.0 [updated March 2014], Review Manager (RevMan) [Computer program]. Version 5.3.0. www.cochrane-handbook.org
  13. 13.Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis [J]. Clin Nutr, 2015,34(6):1101–1108. pmid:25618800
  14. 14.Liu M, Gao Y, Yuan Y, et al. Efficacy and safety of integrated traditional Chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis [J]. Pharmacol Res, 2020, 158:104896. pmid:32438037
  15. 15.Duan C, Xia GW, Zheng CJ, et al. Clinical observation on Jinhua Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus disease 2019 [J]. J Tradit Chin Med, 2020,61(17):1473–1477.
  16. 16.Fu XX, Lin LP, Tan XX. Clinical observation on effect of Toujie Quwen granules in treatment of COVID-19 [J]. Chin J Exp Tradit Med Formul, 2020,26(12):44–48.
  17. 17.Fu XX, Lin LP, Tan XX. Clinical study on 37 case of COVID- 19 treated with integrated traditional Chinese and western medicine [J]. Tradit Chin Drug Res Clin Pharmacol, 2020,31(05):600–604.
  18. 18.Hu F, Guo AH, Huang L, et al. Multi-center clinical observation of Jinyinhua oral liquid combined with western medicine in treatment of moderate COVID-19 [J/OL]. J Tradit Chin Med:1–6[2020-11-4]. http://kns.cnki.net/kcms/detail/11.2166.R.20200819.0837.002.html.
  19. 19.Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [J/OL]. Phytomedicine: 153242[2020-05-16]. https://pubmed.ncbi.nlm.nih.gov/32425361/
  20. 20.Qiu M, Li QT, Zhu DP, et al. Efficacy observation of Maxing Xuanfei Jiedu decoction on moderate COVID-19 patients [J]. J Emerg Tradit Chin Med,2020,29(07):1129–1130+1132.
  21. 21.Sun HM, Xu F, Zhang L, et al. Study on clinical efficacy of Lianhua Qingke granule in treatment of mild and ordinary COVID-19 [J]. Chin J Exp Tradit Med Formul,2020,26(14):29–34.
  22. 22.Yang MB, Dang SS, Haung S, et al. Multi-center clinical observation of Reyanning mixture in treatment of COVID-19 [J]. Chin J Exp Tradit Med Formul,2020,26(14):7–12.
  23. 23.Yu P, Li YZ, Wan SB, et al. Clinical efficacy of Lianhua Qingwen granule combined with abidol in treating coronavirus disease 2019 [J]. Chin Pharm J,2020,55(12):1042–1045.
  24. 24.Zhang CT, Yang Y, You FM, et al. Clinical study on COVID-19 from the perspective of "Yidujiashi" theory [J]. Pharmacol Clin Chin Materia Medica,2020,36(02):43–45.
  25. 25.Zhang YL, Lei L, Xu Y, et al. Clinical efficacy of Jinyinhua oral liquid in the treatment of 80 patients with coronavirus disease 2019 [J]. Chin Pharm,2020,29(09):23–26.
  26. 26.Zhou WM, Zhao FM, Li BL, et al. Clinical value of diammonium glycyrrhizinate in treatment of COVID-19 [J]. Chin J Virol,2020,36(02):160–164.
  27. 27.Professional Committee of infection and inflammation radiology of Chinese Research Hospital Association. Guidelines for Imaging Assisted Diagnosis of COVID-19 [J]. Chin J Med Imaging Technol,2020, 36(3):1–11.
  28. 28.Ministry of Health of the People’s Republic of China. Guiding Principles for Clinical Research of New Chinese Materia Medica [M]. Beijing: China Medical Science and Technology Press, 2002:186.
  29. 29.Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020,395(10223):507–513. pmid:32007143
  30. 30.Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. JAMA, 2020, 323(11): 1061–1069. pmid:32031570
  31. 31.Xiong X, Wang P, Su K, et al. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis [J]. Pharmacol Res, 2020, 160:105056. pmid:32622723
  32. 32.Zeng M, Li L, Wu Z. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials [J]. PLoS One, 2020, 15(9): e0238828. pmid:32915877
  33. 33.Ang L, Song E, Lee HW, et al. Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials [J]. J Clin Med, 2020,9(5):1583.
  34. 34.Yang J. Warm Diseases [M]. Beijing: People’s Health Publishing House, 2006.
  35. 35.Gao D, Niu M, Wei SZ, et al. Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection [J]. Front Pharmacol, 2020,11:746. pmid:32523531
  36. 36.Xia QD, Xun Y, Lu JL, et al. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19 [J]. Cell Prolif, 2020,53(12):e12949. pmid:33140889
  37. 37.Ye M, Luo G, Ye D, et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia [J/OL]. Phytomedicine: 153401 [2020-10-28]. https://pubmed.ncbi.nlm.nih.gov/33191068/
  38. 38.Gao M, Li X, He L, et al. Diammonium glycyrrhizinate mitigates liver injury via inhibiting proliferation of NKT cells and promoting proliferation of tregs [J]. Drug Des Devel Ther,2019,13:3579–3589. pmid:31802846
  39. 39.Zhou XN, Dong Q, Kan XZ, et al. Immunomodulatory activity of a novel polysaccharide from Lonicera japonica immunosuppressed mice induced by cyclophosphamide [J]. PloS one,2018,13(10):1–15.
  40. 40.Bai XY, Chai YW, Shi WL, et al. Lonicera japonica poly-saccharides attenuate ovalbumin-induced allergic rhinitis by regulation of Th17 cells in BALB/c mice [J]. J Functional Foods,2020,65:103758.
  41. 41.Wang J, Hou L, Chen YQ, et al. Extraction and purification of the Lonicera japonica polysaccharide and its antiviral activity in vitro [J]. Chin J Hosp Pharm, 2018,38(8): 810–812.
  42. 42.Qu XY, Li QJ, Zhang HM, et al. Protective effects of phillyrin against influenza a virus in vivo [J]. Arch Pharm Res, 2016, 39(7):998–1005.29. pmid:27323762
  43. 43.Jiang Q, Chen J, Long X, et al. Phillyrin protects mice from traumatic brain injury by inhibiting the inflammation of microglia via PPARγ signaling pathway [J]. Int Immunopharmacol, 2020,79:106083. pmid:31923823
  44. 44.He W, Ma J, Chen Y, et al. Ephedrine hydrochloride protects mice from staphylococcus aureus-induced peritonitis [J]. Am J Transl Res, 2018,10(3):670–683. pmid:29636858
  45. 45.Wei W, Du H, Shao C, et al. Screening of antiviral components of Ma Huang Tang and investigation on the ephedra alkaloids efficacy on influenza virus type A [J]. Front Pharmacol, 2019,10:961. pmid:31551774
  46. 46.Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis [J]. Am J Emerg Med, 2020,38(10):2153–2159. pmid:33071103
  47. 47.Ganji A, Farahani I, Khansarinejad B, et al. Increased expression of CD8 marker on T-cells in COVID-19 patients [J]. Blood Cells Mol Dis, 2020,83:102437. pmid:32325421
  48. 48.Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 [J]. J Clin Invest, 2020,130(5):2620–2629. pmid:32217835
  49. 49.Yan W, Chen D, Bigambo FM, et al. Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis [J]. BMC Infect Dis, 2021,21(1):156. pmid:33557779
  50. 50.Fara A, Mitrev Z, Rosalia RA, et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines [J]. Open Biol,2020,10(9):200160. pmid:32961074
  51. 51.Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far [J]. Front Immunol, 2020,11:1446. pmid:32612617

Plaats een reactie ...

Reageer op "TCM - Traditionele Chinese Medicijnen aanvullend op westerse aanpak is effectiever bij patienten met milde tot matige COVID-19 - coronavirus"

Gerelateerde artikelen

Gerelateerde artikelen

Natuurlijke immuniteit lijkt >> FDA geeft toestemming voor >> Een dubbele infectie van een >> Vitamine D suppletie geeft >> Natuurlijke immuniteit geeft >> Passieve immuniteit kan 60 >> Sotrovimab - Xevudy, een monoklonaal >> De mond spoelen met Aroniasap, >> Nieuwe Chinese Covid-19-antilichaambehandeling >> In Japan lijkt pandemie onder >>